Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Income: 2015-2025

Historic Net Income for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$21.9 million.

  • Seres Therapeutics' Net Income fell 115.63% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year decrease of 184.78%. This contributed to the annual value of $125.9 million for FY2024, which is 64.79% up from last year.
  • Per Seres Therapeutics' latest filing, its Net Income stood at -$21.9 million for Q3 2025, which was up 10.17% from -$24.3 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Net Income registered a high of $139.8 million during Q3 2024, and its lowest value of -$71.5 million during Q1 2023.
  • Moreover, its 3-year median value for Net Income was -$7.2 million (2024), whereas its average is -$1.1 million.
  • Data for Seres Therapeutics' Net Income shows a peak YoY increase of 2,144.32% (in 2024) and a maximum YoY decrease of 334.82% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Net Income stood at -$49.7 million in 2021, then spiked by 95.58% to -$2.2 million in 2022, then crashed by 197.27% to -$6.5 million in 2023, then tumbled by 334.82% to -$28.4 million in 2024, then tumbled by 115.63% to -$21.9 million in 2025.
  • Its last three reported values are -$21.9 million in Q3 2025, -$24.3 million for Q2 2025, and -$26.6 million during Q1 2025.